Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)

Recruiting now · Not applicable

Conditions studied: Myeloproliferative Neoplasm, Myeloproliferative Disorders

In brief

Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.

Key facts

Study ID

NCT07119970

Run by

University Hospital, Bordeaux

People needed

300

Starts

2025-12-09

Expected to finish

2030-12-01

Last updated by the study team

2026-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF)
• JAK2V617F mutation with an allelic burden greater than 1%
• High risk of thrombosis (age over 60 years or prior thrombotic event)
• Diagnosis of MPN within the last 12 months
• Enrollment in the AVAJAK clinical trial and the FIMBANK biobank
• Affiliation with social security
• Signed informed consent

You may not qualify if…

• Severe hepatic or renal insufficiency (Creatinine clearance <30ml/min)
• Patients under legal protection (guardianship or curatorship)
• Patients under heparin treatment at inclusion

Where it is running

• CH de Libourne, Service Hématologie — Libourne, France (enrolling)
• CH de la Côte Basque, Service Hématologie — Bayonne, France
• CHU de Bordeaux, Service Hématologie Biologique — Bordeaux, France
• CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire — Bordeaux, France
• CHU de Brest, Service Hématologie et Hémostase Clinique — Brest, France
• APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire — Créteil, France
• CHD de Vendée, Service Onco-hématologie — La Roche-sur-Yon, France
• APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire — Le Kremlin-Bicêtre, France
• CHU de Limoges, Service Hématologie Clinique et de Thérapie Cellulaire — Limoges, France
• CH des Pays de Morlaix, Service Onco-Hématologie — Morlaix, France
• CHU de Nantes, Service Hématologie Clinique — Nantes, France
• Hôpital Privé du Confluent, Service Hématologie — Nantes, France
• APHO-Hôpital Saint-Louis, Centre d'Investigations Cliniques — Paris, France
• CHU d'Angers, Service des maladies du Sang — Angers, France
• CH de Roubaix, Service Hématologie — Roubaix, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.